Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer". . Cancer 2023 Oct 13. doi: 10.1002/cncr.35064.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer". Cancer 2023 Oct 13. doi: 10.1002/cncr.35064.
PMID: 37831808